论文部分内容阅读
目的分析利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效与安全性。方法应用循证医学方法,从知网检索获得利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的文献21篇,并进行系统分析,借助对比试验组与对照组的治疗总有效率及治疗前后低密度脂蛋白胆固醇(LDL-C)、收缩压(SBP)、腰围(WC)、体质量指数(BMI)以及胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)等指标,对相关文献的结果进行分析。结果试验组治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,试验组患者的LDL-C、SBP、WC、BMI以及HOMA-IR指标均明显低于治疗前和对照组治疗后,HOMA-β水平明显高于治疗前和对照组治疗后,差异均有统计学意义(P<0.05)。结论对于患有肥胖2型糖尿病的患者,采用利拉鲁肽联合胰岛素治疗法不仅能够对血糖进行有效控制,而且显著降低胰岛素的使用量,降低低血糖等不良反应的发生率,同时保护β细胞,改善患者体内胰岛β细胞的功能,还具有一定的减肥作用,是一种优质的治疗方案。
Objective To analyze the efficacy and safety of liraglutide plus insulin in the treatment of obese type 2 diabetes mellitus. Methods 21 cases of type 2 diabetes treated with liraglutide plus insulin were systematically analyzed by evidence-based medical method. The total effective rate of treatment group and control group before and after treatment were compared with those of low-density LDL-C, SBP, WC, BMI, HOMA-IR and HOMA-β, The results of the analysis. Results The total effective rate of the experimental group was significantly higher than that of the control group (P <0.05). After treatment, the indexes of LDL-C, SBP, WC, BMI and HOMA-IR in the experimental group were significantly lower than those in the control group Before treatment and control group, HOMA-β level was significantly higher than before treatment and control group after treatment, the difference was statistically significant (P <0.05). Conclusion In patients with obese type 2 diabetes, the combination of liraglutide and insulin not only provides effective control of blood glucose, but also significantly reduces the amount of insulin used and the incidence of adverse reactions such as hypoglycemia, while protecting the beta cells , To improve the function of pancreatic islet β cells in patients, but also has some weight-loss, is a high-quality treatment options.